Tilray Brands posts record Q1 revenue of $257m, up 23% year-on-year
Tilray Brands has reported record first-quarter net revenue of $257.1 million for the three months ended 31 August 2026, a 23% increase on the $209.5 million reported in the same period a year earlier. Gross profit rose 35% year-on-year to $77.5 million, with group gross margin expanding by approximately 300 basis points to 30%.
The NASDAQ- and TSX-listed company, which operates across cannabis, beverages, pharmaceutical distribution and wellness, said the result reflected momentum across all major geographies and the growing contribution of its BrewDog acquisition, completed earlier in the fiscal year.
Segment performance
Beverage was the standout division, with net revenue rising 82% to $101.5 million and gross margin improving three percentage points to 41%. The company said BrewDog achieved profitability in the quarter. Cannabis net revenue, by contrast, declined to $56.1 million from $64.5 million, with Canadian adult-use sales softening; international cannabis revenues of $16.2 million provided a partial offset, up from $13.4 million a year earlier. The pharmaceutical distribution segment posted revenue of $84.3 million, up 14%, though its gross margin held flat at 11%. Wellness revenue was broadly unchanged at $15.3 million.
Irwin D. Simon, chairman and chief executive, said the results demonstrated that the company was "no longer dependent on a single market or regulatory catalyst" and had built "multiple engines of growth" capable of converting scale into improved margins.
On a reported basis, the quarter produced a net loss of $40.0 million, or $0.32 per share, driven predominantly by non-cash charges. Adjusted EBITDA came in at $9.2 million, slightly below the $10.2 million recorded a year earlier and burdened, the company said, by approximately $1.7 million of global fuel surcharges. The company reaffirmed its full-year adjusted EBITDA guidance of $68 million to $75 million, representing double-digit growth on fiscal 2026.
Market context and competitive landscape
Tilray's pivot towards beverages and pharmaceutical distribution reflects a broader strategic reality in the global cannabis sector: regulatory catalysts, particularly in the United States, have repeatedly failed to materialise on the timescales the market anticipated. Federal cannabis rescheduling in the US remains unresolved, and companies with concentrated exposure to a single jurisdiction have faced significant revenue headwinds. Tilray's multi-category model, built through a series of acquisitions including SweetWater Brewing, Montauk Brewing and now BrewDog, is designed to provide revenue insulation during this regulatory waiting period.
The company's position as the fourth-largest craft brewer in the US and the largest in the UK gives it genuine commercial scale in a category that does not depend on cannabis legalisation. The partnership with Carlsberg, under which Tilray will begin producing and selling Carlsberg brands in the US market from January 2027, is a notable near-term catalyst that could accelerate beverage revenue further in the second half of the fiscal year.
Nonetheless, the declining Canadian cannabis revenue line merits attention. The domestic adult-use market in Canada has been characterised by persistent price compression and intense competition from a large number of licensed producers. Tilray's 39% cannabis gross margin holds up reasonably well relative to the sector average, but the absolute revenue decline underlines the challenge of growing volume in a structurally pressured market.
Investors will focus on the pace of BrewDog integration, the Carlsberg production ramp, and any development in the US cannabis regulatory environment as the key variables shaping Tilray's second-half performance and its ability to deliver within the guided EBITDA range.